Co-Authors
This is a "connection" page, showing publications co-authored by Wendy Stock and Gregory Roloff.
Connection Strength
1.045
-
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
Score: 0.218
-
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 02 10; 43(5):558-566.
Score: 0.218
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.200
-
Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood. 2026 08 06; 148(6):657-668.
Score: 0.062
-
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 04 23; 147(17):2011-2017.
Score: 0.060
-
Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors. Haematologica. 2026 Jul 01; 111(7):2451-2456.
Score: 0.059
-
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
Score: 0.058
-
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2025 11; 60(11):1465-1471.
Score: 0.058
-
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
Score: 0.057
-
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
Score: 0.055